Baxter International Inc. (BAX)
| Previous Close | 39.38 |
| Open | 39.50 |
| Bid | 39.83 x 1000 |
| Ask | 39.85 x 800 |
| Day's Range | 39.47 - 40.02 |
| 52 Week Range | 31.01 - 44.01 |
| Volume | |
| Avg. Volume | 4,607,924 |
| Market Cap | 20.366B |
| Beta (5Y Monthly) | 0.59 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.30 |
| Earnings Date | Oct 31, 2024 - Nov 04, 2024 |
| Forward Dividend & Yield | 1.16 (2.95%) |
| Ex-Dividend Date | Aug 30, 2024 |
| 1y Target Est | 40.65 |
- Business Wire
Baxter Appoints Jeffrey A. Craig to Its Board
DEERFIELD, Ill., September 09, 2024--Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced it has appointed Jeffrey (Jay) A. Craig, former executive chair and chief executive officer (CEO) of Meritor Corporation, to its board of directors. Mr. Craig will serve on Baxter’s Audit Committee. His appointment is effective today and brings the total number of directors serving the company to 12.
GlobeNewswireSpectral Medical Provides August Tigris Trial Update
Management provides view on recently announced Vantive-Carlyle Group transactionTORONTO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and septic shoc
- Business Wire
Baxter to Present at 2024 Wells Fargo Healthcare Conference
DEERFIELD, Ill., August 28, 2024--Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the 2024 Wells Fargo Healthcare Conference on Thursday, September 5, 2024. Joel Grade, Baxter’s chief financial officer, is scheduled to present at 1:30 p.m. Eastern Time.
